Rituximab resistance in ITP and beyond

Keyphrases

• Adaptive Immune Response 50%
• Added Benefit 50%
• B Cells 100%
• Cell-to-cell 100%
• FcRn 50%
• Immune Thrombocytopenia 100%
• Inducing Treatment 50%
• Innate Immune Response 50%
• Megakaryocytes 50%
• Novel Therapeutics 100%
• Novel Therapies 50%
• Over 50 50%
• Pathogenic Mechanism 50%
• Plasma Cells 100%
• Potential Therapeutics 50%
• Resistance Development 50%
• Rituximab 50%
• Rituximab Resistance 100%
• Splenectomy 50%
• T Cells 100%
• Therapeutic Interventions 50%
• Treatment-free Remission 50%

Immunology and Microbiology

• Adaptive Immune System 33%
• B Cell 66%
• Idiopathic Thrombocytopenic Purpura 100%
• Immunoglobulin Producing Cell 66%
• Innate Immune System 33%
• Megakaryocyte 33%
• Rituximab 100%
• T Cell 66%

Pharmacology, Toxicology and Pharmaceutical Science

• Idiopathic Thrombocytopenic Purpura 100%
• Pathophysiology 33%
• Remission 33%
• Rituximab 100%